We report the response to risperidone in seven hospitalized, adult patients who presented psychotic symptoms etiologically related to a general medical condition. The conditions included brain surgery in two, and anticardiolipin syndrome, renal failure, epilepsy, lupus, and metastatic carcinoma in one each. Four patients had failed previous treatment with at least one typical antipsychotic agent. Response to risperidone was assessed by the Brief Psychiatric Rating Scale (BPRS). Serum was collected for measurement of steady-state trough risperidone and 9-hydroxyrisperidone concentrations at effective doses in three patients. Amelioration of psychotic symptoms was noted in all seven patients. Mean (+/- SD) BPRS scores were reduced significantly from baseline (63.0 +/- 15.1) to endpoint (27.0 +/- 3.5; p < 0.01). The mean effective daily dose of risperidone was 3.1 +/- .7 mg and time to response was 4.7 +/- 2.4 days. Risperidone was not present at detectable concentrations in the three patients studied. The mean steady-state trough serum concentration of 9-hydroxyrisperidone in the three patients assessed was 20.3 +/- 9.8 ng/ml. These preliminary findings, which suggest that risperidone is a safe and effective agent in patients with psychotic symptoms due to various medical conditions, need to be confirmed by randomized, antipsychotic comparison trials involving a larger number of patients.

译文

我们报告了7名住院成年患者对利培酮的反应,这些患者表现出与一般医疗状况相关的精神病症状。疾病包括两种脑部手术,以及抗心磷脂综合征,肾衰竭,癫痫,狼疮和转移性癌各一种。四名患者先前使用至少一种典型的抗精神病药治疗失败。通过简明精神病评定量表 (BPRS) 评估对利培酮的反应。在三名患者中以有效剂量收集血清以测量稳态谷利培酮和9-羟基利培酮浓度。所有7例患者的精神病症状均得到改善。平均 (+/- SD) BPRS评分从基线 (63.0 +/- 15.1) 到终点 (27.0 +/- 3.5; p < 0.01) 显著降低。利培酮的平均有效日剂量为3.1 +/- .7 mg,反应时间为4.7 +/- 2.4天。在研究的三名患者中,利培酮不存在可检测的浓度。在评估的三名患者中,9-羟基利培酮的平均稳态谷血清浓度为20.3/- 9.8 ng/ml。这些初步发现表明,利培酮是一种安全有效的药物,用于由于各种医疗条件引起的精神病症状的患者,需要通过涉及更多患者的随机抗精神病比较试验来证实。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录